- Home
- TRIN vs RCUS Comparison
TRIN vs RCUS Comparison
Compare TRIN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- RCUS
- Stock Information
- Founded
- TRIN 2007
- RCUS 2015
- Country
- TRIN United States
- RCUS United States
- Employees
- TRIN N/A
- RCUS N/A
- Industry
- TRIN Finance/Investors Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- TRIN Finance
- RCUS Health Care
- Exchange
- TRIN Nasdaq
- RCUS Nasdaq
- Market Cap
- TRIN 912.3M
- RCUS 906.4M
- IPO Year
- TRIN 2021
- RCUS 2018
- Fundamental
- Price
- TRIN $14.56
- RCUS $8.92
- Analyst Decision
- TRIN Hold
- RCUS Buy
- Analyst Count
- TRIN 3
- RCUS 11
- Target Price
- TRIN $14.83
- RCUS $25.33
- AVG Volume (30 Days)
- TRIN 495.3K
- RCUS 1.2M
- Earning Date
- TRIN 05-07-2025
- RCUS 05-06-2025
- Dividend Yield
- TRIN 14.01%
- RCUS N/A
- EPS Growth
- TRIN 37.77
- RCUS N/A
- EPS
- TRIN 2.19
- RCUS N/A
- Revenue
- TRIN $240,010,000.00
- RCUS $141,000,000.00
- Revenue This Year
- TRIN $24.43
- RCUS N/A
- Revenue Next Year
- TRIN $6.17
- RCUS $29.83
- P/E Ratio
- TRIN $6.65
- RCUS N/A
- Revenue Growth
- TRIN 30.65
- RCUS N/A
- 52 Week Low
- TRIN $12.50
- RCUS $6.50
- 52 Week High
- TRIN $16.82
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- TRIN 49.02
- RCUS 53.03
- Support Level
- TRIN $14.28
- RCUS $8.42
- Resistance Level
- TRIN $14.78
- RCUS $9.61
- Average True Range (ATR)
- TRIN 0.22
- RCUS 0.49
- MACD
- TRIN 0.01
- RCUS 0.06
- Stochastic Oscillator
- TRIN 36.35
- RCUS 48.89
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.